EnZen Invests in Thirona to Help Develop Topical Fibrosis Therapy

EnZen Invests in Thirona to Help Develop Topical Fibrosis Therapy

304857

EnZen Invests in Thirona to Help Develop Topical Fibrosis Therapy

Thirona Bio has partnered with EnZen Therapeutics to accelerate the development of its experimental topical therapy FBM5712 for scleroderma and other conditions associated with scarring (fibrosis). EnZen’s investment in Thirona, part of a convertible promissory note arrangement, may be converted into equity in the long run. The companies will also discuss a potential agreement whereby EnZen’s parent company, Encube Ethicals, would manufacture FBM5712 in a current good manufacturing practice (cGMP) facility on behalf of Thirona…

You must be logged in to read/download the full post.